BioSpace News Archive

Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrime TM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials.

Florida Cancer Specialists & Research Institute, LLC announced that Lucio Gordan, MD has assumed the role of President & Managing Physician, effective January 16, 2023.

PetDx® – The Liquid Biopsy Company for Pets™ has released a white paper demonstrating that OncoK9®, its pioneering multi-cancer early detection test for dogs, can enhance cancer monitoring in canine patients with a simple blood draw.

The nation’s leading ophthalmic surgeons find the ZEPTO IOL Positioning System™ from Centricity Vision Inc. improves the precision and efficiency of cataract surgery, while enabling the growing trend of office-based surgeries preferred for patient comfort and convenience.

The Barbara Ann Karmanos Cancer Institute kicks off year two of its “Inspired” campaign, inviting the community to view a cancer diagnosis not as an ending but as an opportunity to think bigger, think broader, think “Cancer is a Beginning.”

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate

Guerbet, a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Pharmascience Canada launches the generic Prpms-TOFACITINIB in the Canadian market, last November 2022.

Agilis RoboticsTM, a leading developer of flexible robotic instruments that support endoscopic surgery through natural orifices of the body, has recently completed the second round of live animal testing using its proprietary robot.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, “Simcere”).